{"nctId":"NCT02104804","briefTitle":"Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","startDateStruct":{"date":"2014-05-07","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":953,"armGroups":[{"label":"Saxagliptin 5mg","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin 5mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for Saxagliptin"]}],"interventions":[{"name":"Saxagliptin 5mg","otherNames":["Insulin: intermediate-acting or basal or premixed ( include short- or rapid-acting insulin as one component). ≥20 unit/day, ≤150 units/day","Metformin: Glucophage, 500-2500mg/day"]},{"name":"Placebo for Saxagliptin","otherNames":["Insulin: intermediate-acting or basal or premixed ( include short- or rapid-acting insulin as one component). ≥20 unit/day, ≤150 units/day","Metformin: Glucophage, 500-2500mg/day"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Provision of informed consent before participating in the study.\n2. Diagnosed with type 2 diabetes.\n3. Inadequate glycemic control (screening: HbA1c ≥7.5% and ≤11.0% and FPG\\<270 mg/dL (15mmol/L). At Day -4 visit, HbA1c ≥7.5% and ≤10.5%. and FPG\\<270 mg/dL (15mmol/L)).\n4. On a stable dose of insulin for 8 weeks or longer prior to screening.\n5. If taking metformin, subjects should have been taking the same daily dose for 8 weeks or longer prior to screening.\n6. Insulin type should be intermediate-acting or long-acting (basal) or premixed (premixed formulation may include short- or rapid-acting insulin as one component).\n7. Body mass index ≤45 kg/m\\^2.\n\nExclusion Criteria:\n\n1. Women of childbearing potential unable or unwilling to use acceptable birth control.\n2. Women who are pregnant or breastfeeding.\n3. Symptoms of poorly controlled diabetes. including but not limited to, marked polyuria and polydipsia with greater than 10% weight loss during the last three months prior to screening or other signs and symptoms.\n4. Significant cardiovascular history defined as: myocardial infarction, coronary angioplasty or bypass graft, valvular disease or repair, unstable clinical significant arrhythmia, unstable angina pectoris, transient ischemic attack, or cerebrovascular accident.\n5. Congestive heart failure\n6. Chronic or repeated intermittent corticosteroid treatment (subjects receiving stable doses of replacement corticosteroid (except dexamethasone) therapy may be enrolled).\n7. History of unstable or rapidly progressing renal disease.\n8. History of alcohol or drug abuse within the previous year.\n9. Unstable major psychiatric disorders.\n10. History of hemoglobinopathies\n11. Immunocompromised status\n12. Severe liver disease.\n13. In subjects treated with insulin alone a calculated creatinine clearance \\<50 ml/min. In patients treated with insulin in combination with metformin a calculated creatinine clearance \\<60 ml/min or serum creatinine \\> 1.5 mg/dL in males or \\> 1.4mg/dL in females.\n14. Anemia","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 24","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":null},{"groupId":"OG001","value":"-0.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Postprandial Glucose AUC From Baseline to Week 24 During a Meal Tolerance Test","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4702.2","spread":null},{"groupId":"OG001","value":"1431.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Analysis of Change in 120-minute PPG From Baseline to Week 24 During a Meal Tolerance Test","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.28","spread":null},{"groupId":"OG001","value":"8.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving a Therapeutic Glycaemic Response of HbA1c <7%","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"The Analysis of Change in Fasting Plasma Glucose From Baseline to Week 24 (This Was the Average of Weeks 20 and 24)","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.23","spread":null},{"groupId":"OG001","value":"4.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Analysis of Change in Mean Total Daily Dose of Insulin From Baseline to Week 24","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":231},"commonTop":["Hypoglycaemia","Upper respiratory tract infection","Nasopharyngitis","Urinary tract infection","Cough"]}}}